Snowden Capital Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Snowden Capital Advisors’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,100	Closed	-$78K	–	1761
2021 Q4	$78K	Buy	+1,100	New	+$79.6K	﹤0.01%	913

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

AWA

Artemis Wealth Advisors New York $662M AUM 39.67% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

IFWM

Institute for Wealth Management Denver, Colorado $938M AUM 29.36% 1-Year Est. Return

Snowden Capital Advisors's PBE Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2022, closing a stake of 1,100 shares — an estimated $78K sold.

Snowden Capital Advisors first reported a position in PBE in Q4 2021 and held it in 1 quarter. The position peaked at $78K in Q4 2021. 89 funds tracked by Wall St. Rank hold PBE as of Q1 2022.

Snowden Capital Advisors reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 1,100 Invesco Biotechnology & Genome ETF shares in Q1 2022, an estimated $78K.
Snowden Capital Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's Invesco Biotechnology & Genome ETF position peaked at $78K in Q4 2021.
89 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.